Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort

Bipasha Biswas, Edward Spitznagel, Ann C. Collier, Benjamin Gelman, Justin C. McArthur, Susan Morgello, J. Allen McCutchan, David B. Clifford

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95%. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95%. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.

Original languageEnglish (US)
Pages (from-to)8-25
Number of pages18
JournalJournal of HIV/AIDS and Social Services
Volume13
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Cohort Effect
Medication Adherence
Acquired Immunodeficiency Syndrome
AIDS
medication
Central Nervous System
HIV
Research
experience
suppression
Therapeutics
research practice
Viral Load
Appointments and Schedules
illness
Cross-Sectional Studies
RNA
Depression

Keywords

  • adherence
  • depressive symptomatology
  • HIV/AIDS transmission and/or risk
  • immune markers
  • treatment issues

ASJC Scopus subject areas

  • Health(social science)

Cite this

Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS : Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort. / Biswas, Bipasha; Spitznagel, Edward; Collier, Ann C.; Gelman, Benjamin; McArthur, Justin C.; Morgello, Susan; McCutchan, J. Allen; Clifford, David B.

In: Journal of HIV/AIDS and Social Services, Vol. 13, No. 1, 2014, p. 8-25.

Research output: Contribution to journalArticle

Biswas, Bipasha ; Spitznagel, Edward ; Collier, Ann C. ; Gelman, Benjamin ; McArthur, Justin C. ; Morgello, Susan ; McCutchan, J. Allen ; Clifford, David B. / Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS : Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort. In: Journal of HIV/AIDS and Social Services. 2014 ; Vol. 13, No. 1. pp. 8-25.
@article{33e7115bbd35461580cc5499cb0082bb,
title = "Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort",
abstract = "Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95{\%}. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95{\%}. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.",
keywords = "adherence, depressive symptomatology, HIV/AIDS transmission and/or risk, immune markers, treatment issues",
author = "Bipasha Biswas and Edward Spitznagel and Collier, {Ann C.} and Benjamin Gelman and McArthur, {Justin C.} and Susan Morgello and McCutchan, {J. Allen} and Clifford, {David B.}",
year = "2014",
doi = "10.1080/15381501.2013.859111",
language = "English (US)",
volume = "13",
pages = "8--25",
journal = "Journal of HIV/AIDS and Social Services",
issn = "1538-1501",
publisher = "Routledge",
number = "1",

}

TY - JOUR

T1 - Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS

T2 - Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort

AU - Biswas, Bipasha

AU - Spitznagel, Edward

AU - Collier, Ann C.

AU - Gelman, Benjamin

AU - McArthur, Justin C.

AU - Morgello, Susan

AU - McCutchan, J. Allen

AU - Clifford, David B.

PY - 2014

Y1 - 2014

N2 - Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95%. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95%. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.

AB - Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95%. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95%. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.

KW - adherence

KW - depressive symptomatology

KW - HIV/AIDS transmission and/or risk

KW - immune markers

KW - treatment issues

UR - http://www.scopus.com/inward/record.url?scp=84895744998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895744998&partnerID=8YFLogxK

U2 - 10.1080/15381501.2013.859111

DO - 10.1080/15381501.2013.859111

M3 - Article

AN - SCOPUS:84895744998

VL - 13

SP - 8

EP - 25

JO - Journal of HIV/AIDS and Social Services

JF - Journal of HIV/AIDS and Social Services

SN - 1538-1501

IS - 1

ER -